So what to make of the recent white-knuckle gyrations on Wall Street? Our contributor Ben Stein haSo what to "So what to make of the recent white-knuckle gyrations on Wall Street? Our contributor Ben Stein has some thoughts on that: August is the cruelest month.
August is the cruelest month.A good chunk of my savings disappeared as the stock market convulsed, and we're down at some pointswell over 10 percent. Why did it happen?
The pundits and analysts appeared and said it was because of the Chinese devaluation and possible serious weakness in China. This, in turn, would devastate U.S. exports, supposedly, to China and sink the ship of our prosperity.That was, and is, nonsense.
The U.S. economy's output is roughly $18.4 trillion per year. Total exports to China are very roughly $120 billion per year.
That a lot of hamburgers, but it's roughly seven-tenths of one percent of the U.S. economy.
If our exports to China fell by 20 percent -- a large number -- that would have only trifling effect on the U.S. economy -- very roughly one-tenth of one percent of U.S. output, trivial even for an economy as big as ours.
But at some moments the U.S. stock markets were off by more than a stupendous $2 TRILLION.
When the stock markets move 1,000 points in a few minutes, it's not because you and I are selling 1,000 shares of GE from our home computer. It is because immense hedge funds, high frequency trading funds, endowments and pension funds sell billions of dollars' worth at the push of a button.
They do it because they personally (and their clients) can possibly make immense sums of money on it.
Stocks move on markets because the big boys in New York or Hong Kong or London say to their traders, "Boys and girls, let's move this guy down! Start some rumors about weakness in China, and then sell like mad!"
Tha has been the premise since the very early days when Exelixis started using Drosophila melanogaster. If only this article wasn't talking about xenograft studies; and it were human trials we would really have something concrete.Thanks for sharing everything you come across in your hrs. of research.I appreciate it.Ciao
I see Duke Cancer Institute is doing that study. Cabozantinib (XL184) with Panitumumab in Subjects with KRAS Wild-Type Metastatic I see Colorectal Cancer and Cabozantinib Monotherapy in Subjects with MET Amplified Treatment-Refractory Colorectal Cancer
Title Job ID Location Date Posted
Senior Revenue Accountant 1374 South San Francisco, CA
10070 Help Desk Specialist I 1369 South San Francisco, CA
Accounting Manager 1363 South San Francisco, CA
"Option granted pursuant to the Exelixis, Inc. 2014 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the grant date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the grant date.Date Exercisable 09/16/2016(1) Expiration Date 09/15/2022"
From the form,"Date Exercisable 09/16/2016.Old buddy,they are not able to buy them for a year and then only 1/4 of them at a time.Just as it was for us and everyone else.
On CNBC a clinician said the simple answer to what happened with Daraprim is to include a provision with such a sale, that says the price can't be increased.
Associate Director, FP&A
The Associate Director, FP&A will provide support for all financial aspects primarily in the Commercial area including reporting results, budgeting/forecasting, 3rd party vendor accruals, financial modeling, and analytical and strategic support. This role will also provide support for corporate FP&A activities and integrate seamlessly with the Exelixis internal reporting and planning processes, including monthly reporting, quarterly rolling forecast, annual budget and long range plan. The Position will report to the Vice President, FP&A.
Sorry but you are wrong.The Dr. giving the speech actually said the is already a study combining Cabo and Nivo.Go back and listen to his answer given during the question period.
Just like pain relievers if you were to ask me.They all work: aspirin,Advil etc. etc..Some seem to work well for one person, While another my seem to work better for the next person.Or that is how they feel.A Dr. may tell people take that one. They may have a different opinion than the next Dr. who would choice a different pain reliever. There is room for more than one drug here.
I don't speculate on the hypothetical.It happens if it happens.Past BioTechs I worked at that were M/A's came totally by surprise.Without a clue before hand.The first was bought for $20 plus per share and there was no product; just the tech was wanted.